CD34 and acute myeloid leukemia: Even though the data we presented here are proof of concept, they will ideally be validated using better humanized mouse models, such as immune-deficient mice reconstituted with autologous CD34+ progenitors followed by transplantation of primary AML blasts from the same patients.